AI assistant
GlaxoSmithKline PLC — Director's Dealing 2019
Oct 15, 2019
5262_dirs_2019-10-15_a5317923-6cfb-4185-8fd7-18e1c6ec1bab.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 9646P
GlaxoSmithKline PLC
15 October 2019
GlaxoSmithKline plc (the 'Company')
Transaction notification
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms E Walmsley
b)
Position/status
Chief Executive Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £ 17.1200 | 202.000 |
| £ 17.1200 | 707.000 |
| £ 17.1200 | 704.000 |
| £ 17.1200 | 202.000 |
d)
Aggregated information
Aggregated volume Price
1815.000
£ 17.1200
e)
Date of the transaction
2019-10-14
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr R Connor
b)
Position/status
President, Global Vaccines
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £ 17.1200 | 105.000 |
| £ 17.1200 | 149.000 |
| £ 17.1200 | 184.000 |
| £ 17.1200 | 105.000 |
d)
Aggregated information
Aggregated volume Price
543.000
£ 17.1200
e)
Date of the transaction
2019-10-14
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr N Hirons
b)
Position/status
SVP, Global Ethics & Compliance
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £ 17.1200 | 66.000 |
| £ 17.1200 | 78.000 |
| £ 17.1200 | 77.000 |
| £ 17.1200 | 66.000 |
d)
Aggregated information
Aggregated volume Price
287.000
£ 17.1200
e)
Date of the transaction
2019-10-14
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr L Miels
b)
Position/status
President, Global Pharmaceuticals
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £ 17.1200 | 142.000 |
| £ 17.1200 | 196.000 |
d)
Aggregated information
Aggregated volume Price
338.000
£ 17.1200
e)
Date of the transaction
2019-10-14
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr D Redfern
b)
Position/status
Chief Strategy Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £ 17.1200 | 83.000 |
| £ 17.1200 | 145.000 |
| £ 17.1200 | 174.000 |
| £ 17.1200 | 83.000 |
d)
Aggregated information
Aggregated volume Price
485.000
£ 17.1200
e)
Date of the transaction
2019-10-14
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr R Simard
b)
Position/status
President, Pharmaceuticals Supply Chain
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £ 17.1200 | 63.000 |
d)
Aggregated information
Aggregated volume Price
N/A (single transaction)
e)
Date of the transaction
2019-10-14
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr P Thomson
b)
Position/status
President, Global Affairs
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £ 17.1200 | 79.000 |
| £ 17.1200 | 98.000 |
| £ 17.1200 | 102.000 |
d)
Aggregated information
Aggregated volume Price
279.000
£ 17.1200
e)
Date of the transaction
2019-10-14
f)
Place of the transaction
London Stock Exchange (XLON)
Transaction notification
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr B McNamara
b)
Position/status
CEO, GSK Consumer Healthcare
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
b)
Nature of the transaction
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 10 October 2019 on ADSs held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| $ 42.2500 | 75.000 |
| $ 42.2500 | 74.000 |
| $ 42.2500 | 69.000 |
d)
Aggregated information
Aggregated volume Price
218.000
$ 42.2500
e)
Date of the transaction
2019-10-14
f)
Place of the transaction
New York Stock Exchange (XNYS)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Dr H Barron
b)
Position/status
Chief Scientific Officer and President, R&D
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
b)
Nature of the transaction
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 10 October 2019 on ADSs held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| $ 42.2500 | 413.000 |
d)
Aggregated information
Aggregated volume Price
N/A (single transaction)
e)
Date of the transaction
2019-10-14
f)
Place of the transaction
New York Stock Exchange (XNYS)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr J Ford
b)
Position/status
SVP and General Counsel
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
b)
Nature of the transaction
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 10 October 2019 on ADSs held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| $ 42.2500 | 35.000 |
d)
Aggregated information
Aggregated volume Price
N/A (single transaction)
e)
Date of the transaction
2019-10-14
f)
Place of the transaction
New York Stock Exchange (XNYS)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms K Terrell
b)
Position/status
Chief Digital & Technology Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
b)
Nature of the transaction
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 10 October 2019 on ADSs held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| $ 42.2500 | 25.000 |
| $ 42.2500 | 87.000 |
d)
Aggregated information
Aggregated volume Price
112.000
$ 42.2500
e)
Date of the transaction
2019-10-14
f)
Place of the transaction
New York Stock Exchange (XNYS)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
DSHXELFFKBFBFBZ